NASDAQ: ICVX - Icosavax, Inc.

Yield per half year: 0%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Icosavax, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Icosavax, Inc.

Icosavax, Inc., биофармацевтическая компания, разрабатывает вакцины против инфекционных заболеваний. Компания с помощью своей платформы вирусоподобных частиц (VLP) фокусируется в первую очередь на опасных для жизни респираторных заболеваниях.

more details
Его продукты на стадии разработки: IVX-A12, кандидат в моновалентный антиген респираторно-синцитиального вируса (RSV) с указанием на бивалентную мишень RSV / метапневмовирус человека (hMPV); IVX-121, вакцина-кандидат с мишенью RSV; IVX-241, вакцина-кандидат с мишенью hMPV; IVX-411, антиген последовательности исходного рецепторсвязывающего домена (RBD) с указанием мишени SARS-CoV-2 ^; и IVX-421, вариантный антиген RBD с указанием цели SARS-CoV-2 ^. Компания была зарегистрирована в 2017 году, ее штаб-квартира находится в Сиэтле, штат Вашингтон.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-07-29
ISIN US45114M1099
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://icosavax.com
Цена ао 15.31
Change price per day: 0% (15.31)
Change price per week: 0% (15.31)
Change price per month: 0% (15.31)
Change price per 3 month: 0% (15.31)
Change price per half year: 0% (15.31)
Change price per year: 0% (15.31)
Change price per 3 year: +117.47% (7.04)
Change price per year to date: 0% (15.31)
All parameters

Underestimation

Title Value Grade
P/S 15.6 1
P/BV 1.58 8
P/E 27.8 6
EV/EBITDA -3.09 0
Total: 4.5

Efficiency

Title Value Grade
ROA, % -33.61 0
ROE, % -35.64 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0925 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 35 5
Yield Ebitda, % 1138.89 10
Yield EPS, % -118.97 0
Total: 7
More

Institutions Volume Share, %
RA Capital Management, L.P. 5963565 11.91
FMR, LLC 5453948 10.89
T. Rowe Price Investment Management, Inc. 4835651 9.65
Tcg Crossover Management, Llc 3703704 7.39
Qiming U.s. Ventures Management, Llc 3510228 7.01
Logos Global Management LP 2765741 5.52
Platinum Investment Management Ltd 2335992 4.66
Adams Street Partners, LLC 2179964 4.35
Blackrock Inc. 1996280 3.99
Vanguard Group Inc 1898287 3.79



Head Job title Payment Year of birth
Mr. Adam K. Simpson President, CEO, Co-Founder & Director 855.95k 1976 (49 years)
Mr. Niranjan Kanesa-thasan M.D. Chief Medical Officer 641.55k 1961 (64 years)
Mr. Neil King Ph.D. Chair of Scientific Advisory Board & Co-Founder N/A
Mr. Thomas Joseph Russo C.F.A. Chief Financial Officer 525.27k 1972 (53 years)
Ms. Elizabeth Bekiroglu General Counsel & Corporate Secretary 230.74k 1970 (55 years)
Ms. Lori Stewart Senior Vice President of People & Culture N/A
Dr. David Baker M.D., Ph.D. Co-founder & Member of Scientific Advisory Board N/A
Ms. Jennifer Raymond Senior Vice President of Technical Operations N/A
Dr. Cassia Cearley Ph.D. Treasurer & Chief Business Officer 632.15k 1983 (42 years)
Dr. Ami Shah Brown MPH, Ph.D. Senior Vice President of Regulatory Affairs N/A

Address: United States, Seattle, WA , 1616 Eastlake Avenue E. - open in Google maps, open in Yandex maps
Website: https://icosavax.com